Market Place
Sourcing Support
Eupraxia Pharma To Present At Investor Conferences
13 Apr 2026 //
GLOBENEWSWIRE
Eupraxia Pharma Reveals 6-Month Symptom Data In High-Dose Cohort
17 Mar 2026 //
GLOBENEWSWIRE
Eupraxia Pharma Sets US$55M Public Share Offering Pricing
19 Feb 2026 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals Announces Proposed Public Offering
18 Feb 2026 //
GLOBENEWSWIRE
Eupraxia Reports Near-Complete Biopsy Improvement in EoE Trial
08 Jan 2026 //
GLOBENEWSWIRE
Eupraxia Pharma Reveals 52-Week RESOLVE Trial Follow-Up Data
13 Nov 2025 //
GLOBENEWSWIRE
Eupraxia Pharma Reveals Q3 2025 Financials Updates
04 Nov 2025 //
GLOBENEWSWIRE
Eupraxia Pharma Reveals Strong Results In RESOLVE Trial
29 Sep 2025 //
GLOBENEWSWIRE
Eupraxia Pharma Prices $70m Public Offering Of Common Shares
22 Sep 2025 //
GLOBENEWSWIRE
Eupraxia Pharma Announces Proposed Public Offering of Shares
22 Sep 2025 //
GLOBENEWSWIRE
Resolve Trial Shows EP-104GI Yields Lasting EoE Symptom Relief
02 Sep 2025 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals Q2 2025 Financial Results and Update
12 Aug 2025 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals to Present at Investor Conferences
22 Jul 2025 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals to Host Virtual KOL Event on May 9, 2025
07 May 2025 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results
06 May 2025 //
GLOBENEWSWIRE
Eupraxia Pharmaceuticals Reports Positive EoE Treatment Outcomes
05 May 2025 //
GLOBENEWSWIRE
Eupraxia Pharma Reports Positive Data from EP-104GI Trial
25 Feb 2025 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Announces CFO Succession
18 Feb 2025 //
PR NEWSWIRE
Eupraxia Pharmaceuticals to Present at ACR Convergence 2024
14 Nov 2024 //
PR NEWSWIRE
Eupraxia Announce Positive Data from EP-104GI Trial for Esophagitis
12 Nov 2024 //
PR NEWSWIRE
Eupraxia Pharma Reports Q3 2024 Financial Results
07 Nov 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Closes C$44.5M Private Placement
31 Oct 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals to Present at Gastroenterology Meeting
28 Oct 2024 //
PR NEWSWIRE
Lancet Publishes Ph 2b Data On Eupraxia`s of Knee Osteoarthritis
15 Oct 2024 //
PR NEWSWIRE
Eupraxia To Present At United European Gastroenterology Week 2024
10 Oct 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Strengthens Senior Management Team
02 Oct 2024 //
PR NEWSWIRE
Eupraxia Announces EP-104GI Phase 1b/2a Data For Eosinophilic Esophagitis
11 Sep 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals to Present at H.C. Wainwright Annual Conference
04 Sep 2024 //
PR NEWSWIRE
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
07 Aug 2024 //
PR NEWSWIRE
